Denali Therapeutics Inc
$ 20.57
-0.68%
17 Apr - close price
- Market Cap 3,262,227,000 USD
- Current Price $ 20.57
- High / Low $ 21.37 / 20.54
- Stock P/E N/A
- Book Value 6.49
- EPS -2.97
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.46 %
- 52 Week High 23.77
- 52 Week Low 12.31
About
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$36.21
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-11 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-01 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 | 2023-05-08 |
| Reported EPS | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 | -0.63 | -0.59 | -0.78 | -0.86 | -0.72 | 1.3 | -0.8 |
| Estimated EPS | -0.75 | -0.75 | -0.71 | -0.7043 | -0.8459 | -0.61 | -0.69 | -0.7 | -0.8 | -0.8 | -0.68 | -0.7 |
| Surprise | 0.02 | 0.01 | -0.01 | -0.0757 | 0.1759 | -0.02 | 0.1 | -0.08 | -0.06 | 0.08 | 1.98 | -0.1 |
| Surprise Percentage | 2.6667% | 1.3333% | -1.4085% | -10.7483% | 20.7944% | -3.2787% | 14.4928% | -11.4286% | -7.5% | 10% | 291.1765% | -14.2857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNLI
2026-04-18 16:09:44
Denali Therapeutics (DNLI) saw its stock rise by 7.4% after Takeda Pharmaceutical terminated their collaboration for DNL593, returning all program rights to Denali. This decision, driven by Takeda's internal priorities rather than safety or efficacy concerns, gives Denali full control over a promising Phase 1/2 asset. While regaining control concentrates development costs, it also highlights the importance of Denali's other programs and its blood-brain barrier platform in its investment narrative.
2026-04-16 12:40:19
Denali Therapeutics (DNLI) has regained full control of its DNL593 therapy after Takeda terminated their collaboration agreement. Denali plans to continue the clinical development of DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin, and expects to report Phase 1/2 trial results by the end of 2026. The company also recently secured FDA accelerated approvals for its AVLAYAH product and highlighted the success of its TransportVehicle platform.
2026-04-15 01:38:49
The FDA has approved Denali Therapeutics' drug for the treatment of a rare, inherited neurological disorder known as MPS IIIA or Sanfilippo syndrome. This marks the first time an enzyme replacement therapy has been cleared to enter the brain, offering a potential breakthrough for patients. The drug is designed to cross the blood-brain barrier to deliver the necessary enzyme.
2026-04-11 12:09:03
Denali Therapeutics (DNLI) has experienced a mixed share performance, with a recent pullback but overall gains over three months. The article assesses Denali's valuation, noting its price-to-book (P/B) multiple of 3x is higher than the US biotech average but significantly lower than its peer group, amid expectations of strong pipeline growth despite current net losses. It suggests that while the current price may reflect future growth potential, investors should also consider the inherent risks associated with early-stage biopharma companies.
2026-04-09 12:10:41
Denali Therapeutics recently received accelerated FDA approval for AVLAYAH for Hunter syndrome and simultaneously learned that Takeda will end their co-development agreement for DNL593. These events highlight Denali's shift towards independently advancing its TransportVehicle-based pipeline. While AVLAYAH’s approval validates Denali's platform, the company faces growing reliance on self-funding its capital-intensive pipeline, prompting investors to weigh platform potential against execution, regulatory, and financing risks.
2026-04-08 13:40:25
Healthcare sector analysts have issued bullish sentiments for Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC). H.C. Wainwright maintained a Buy rating for Denali with a $42 price target, while Craig-Hallum maintained a Buy rating for Fennec, which has a consensus price target of $15. Both companies show strong buy consensus from analysts, indicating significant upside potential.
